Amporin Pharmaceuticals AG
- Biotech or pharma, therapeutic R&D
Amporin Pharmaceuticals AG is a Swiss biotech company founded in 2024 by a small team of ex-Pharma drug discovery and development experts. We are developing a breakthrough new class of small molecule "amyloid pore"inhibitors that can uniquely repair the holes in cell membranes formed by toxic soluble misfolded protein oligomers, allowing cells to fully recover and restore homeostasis as the first potential acute oral disease-modifying treatments to stop and reverse over 50 deadly degenerative diseases associated with protein misfolding and aggregation, including Alzheimer's, Parkinson's, Huntington's, ALS, type II diabetes, and many rare degenerative diseases. By directly targeting the fundamental molecular mechanism that causes all these diseases, our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}